The Joseph Osborne Laboratory and Cancer Equity Group has a strong interest in the genetic and socioeconomic causes of the uneven burden of cancer-related mortality. As it is now known that specific tumor genomic mutations can be exploited for more effective diagnosis and treatment, we will further explore how this is reflected in various subpopulations. We believe that this novel approach will have a significant impact on our patients. From the diagnostic perspective, we will continue to have a strong focus on the next generation of molecular imaging probes, but will focus on finding means of cost-effective and practical integration. It is our belief that cost effective diagnostics will translate to broader access to more effective therapeutics. Cancer equity will be addressed by combining these seemingly disparate areas of focus into one goal, dedicated towards the responsible translation of investigational compounds and genomic biomarkers into the communities most at-risk.
- Bedford-Stuyvesant & Bushwick: Cancer Health Impact Program (CHIP) P30-CA008748
- Interventional Culture and Language Assistance Program (ICLAP)
- A new technique to make 68Ga‑labeled pharmaceuticals widely available for clinical use.
The IntersectMSK lecture series is an opportunity for experts outside MSK to collaborate and share insights and experiences on market innovation, trends, policy, startups, venture capital relationships, drug development and product market introduction.
If you would like to additional information, contact us at (212) 639-7788.